03:33 AM EDT, 06/17/2024 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Sunday an ongoing phase 1a/b clinical trial of its drug NX-5948 is yielding what one of its researchers called "impressive" results for the treatment of adult patients with relapsed or refractory B-cell malignant cancers such as non-Hodgkin lymphoma.

Among 26 "efficacy evaluable" patients in the study, 26 showed a "robust objective response rate" of 69.2% across all doses tested, the company said, adding that the responses of "many patients" improved the longer they were under treatment.

Data presented at a conference in Madrid last week also suggested the orally administered drug was safe and well tolerated at various dosages, the company said